MarketCapExport financials
Crinetics Pharmaceuticals (CRNX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Crinetics Pharmaceuticals Balance Sheet 2025-2011 | CRNX
Brief balance sheet overview of Crinetics Pharmaceuticals
The comparison uses five available annual reports from the 2021–2025 interval.
Assets advanced +220.9% to $1.1 billion from $351 million; annual growth near 33.8% reflects a fast increase in scale.
Liabilities grew faster than assets: +603.5% versus +220.9%. A substantial part of expansion was externally funded.
Equity accounts for 88.1% of assets. Against the initial 94.6%, the capital position looks resilient.
The period ended with net cash: net debt stood at -$53 million. This supports financial flexibility.
Cash accounts for 9% of assets versus 57.2% initially. The change indicates the degree of financial flexibility.
The balance sheet carries negative retained earnings of -$1.4 billion. The figure may result from accumulated losses or an active capital return policy.
Overall assessment
Crinetics Pharmaceuticals retains a reasonably healthy balance sheet structure, which still needs support from earnings and cash flow.
Annual Balance Sheet Crinetics Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-53 M | -213 M | -3.17 M | -29.6 M | -198 M | -89.1 M | -35.5 M | -45 M | -14.2 M | -11.9 M | - | - | - | - | - |
Long Term Debt |
42.1 M | 44.6 M | 47.6 M | 2.02 M | 3.07 M | 4.01 M | - | - | - | 163 K | - | - | - | - | - |
Long Term Debt Current |
6.49 M | 7.15 M | 4.17 M | 1.05 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 4.9 M | 3.26 M | 29.7 M | 17.9 M | - | - | - | - | - |
Total Current Liabilities |
85.1 M | 59.7 M | 43.9 M | 27.7 M | 16 M | 10.5 M | 8.34 M | 7.92 M | - | - | - | - | - | - | - |
Total Liabilities |
134 M | 110 M | 96.2 M | 35.8 M | 19.1 M | 14.5 M | 13.2 M | 11.2 M | 30.6 M | 18.8 M | - | - | - | - | - |
Deferred Revenue |
1.24 M | 2.18 M | - | 2.2 M | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.42 B | -952 M | -654 M | -439 M | -275 M | - | -93.8 M | -43.4 M | -16.3 M | -7.11 M | - | - | - | - | - |
Total Assets |
1.13 B | 1.43 B | 635 M | 352 M | 351 M | 183 M | 130 M | 171 M | 15.6 M | 12.6 M | - | - | - | - | - |
Cash and Cash Equivalents |
102 M | 265 M | 54.9 M | 32.7 M | 201 M | 93.1 M | 40.3 M | 45 M | 14.2 M | 12.2 M | - | - | - | - | - |
Book Value |
992 M | 1.32 B | 539 M | 316 M | 332 M | 169 M | 117 M | 160 M | -15 M | -6.2 M | - | - | - | - | - |
Total Shareholders Equity |
992 M | 1.32 B | 539 M | 316 M | 332 M | 169 M | 117 M | 160 M | -15 M | -6.2 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Crinetics Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
40.6 M | 41.3 M | 42.7 M | 43.3 M | 43.9 M | 44.6 M | 45.1 M | 45.9 M | 46.7 M | 47.6 M | 48.2 M | 1.46 M | 1.74 M | 2.02 M | 2.3 M | 2.56 M | 2.82 M | 3.07 M | 3.32 M | 3.56 M | 3.79 M | 4.01 M | 4.01 M | 4.01 M | 4.01 M | 4.85 M | 4.85 M | 4.85 M | 4.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
130 M | 121 M | 124 M | 118 M | 107 M | 110 M | 104 M | 105 M | 103 M | 96.2 M | 93.8 M | 39.1 M | 33.7 M | 35.8 M | 33.5 M | 35.6 M | 30.2 M | 19.1 M | 15.8 M | 15.5 M | 14.1 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 13.2 M | 13.2 M | 13.2 M | 13.2 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 920 K | 920 K | 920 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.67 M | 1.27 M | - | - | - | - | 1.68 M | 2.56 M | - | 2.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.67 B | -1.55 B | -1.29 B | -1.16 B | -1.05 B | -952 M | -872 M | -795 M | -721 M | -654 M | -594 M | -536 M | -485 M | -439 M | -394 M | -352 M | -310 M | -275 M | -244 M | -217 M | -191 M | -168 M | -168 M | -168 M | -168 M | -93.8 M | -93.8 M | -93.8 M | -93.8 M | -43.4 M | -43.4 M | -43.4 M | -43.4 M | -16.3 M | -16.3 M | -16.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.32 B | 1.4 B | 1.2 B | 1.29 B | 1.36 B | 1.43 B | 937 M | 936 M | 978 M | 635 M | 642 M | 293 M | 314 M | 352 M | 385 M | 422 M | 333 M | 351 M | 209 M | 217 M | 164 M | 183 M | 183 M | 183 M | 183 M | 130 M | 130 M | 130 M | 130 M | 171 M | 171 M | 171 M | 171 M | 15.6 M | 15.6 M | 15.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
55.5 M | 114 M | 111 M | 53.7 M | 94.6 M | 265 M | 317 M | 302 M | 396 M | 54.9 M | 143 M | 39.6 M | 41.2 M | 32.7 M | 30.9 M | 62.3 M | 146 M | 201 M | 162 M | 179 M | 106 M | 93.1 M | 93.1 M | 93.1 M | 93.1 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | 45 M | 45 M | 45 M | 45 M | 14.2 M | 14.2 M | 14.2 M | - | 12.2 M | - | - | - | 17.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.19 B | 1.28 B | 1.07 B | 1.17 B | 1.25 B | 1.32 B | 833 M | 831 M | 875 M | 539 M | 548 M | 254 M | 280 M | 316 M | 351 M | 386 M | 303 M | 332 M | 194 M | 201 M | 149 M | 169 M | 169 M | 169 M | 169 M | 117 M | 117 M | 117 M | 117 M | 160 M | 160 M | 160 M | 160 M | 14.7 M | 14.7 M | 14.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.19 B | 1.28 B | 1.07 B | 1.17 B | 1.25 B | 1.32 B | 833 M | 831 M | 875 M | 539 M | 548 M | 254 M | 280 M | 316 M | 351 M | 386 M | 303 M | 332 M | 194 M | 201 M | 149 M | 169 M | 169 M | 169 M | 169 M | 117 M | 117 M | 117 M | 117 M | 160 M | 160 M | 160 M | 160 M | -15 M | -15 M | -15 M | - | -6.2 M | - | - | - | -463 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Crinetics Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Britain
Israel
Germany
Canada
Russia
Schweiz
